A phase IIa double blind, randomised placebo-controlled trial of Tocilizumab to investigate the effect on health-related quality of life in adults with Long COVID and persistent inflammation (PHOSP-I)

Research summary

The hypothesis is that subcutaneous Tocilizumab administered for 12 weeks will improve generic health-related quality of life compared to placebo by reducing systemic inflammation and improving symptoms in adults with Long Covid. Primary outcome - to investigate the effect of 12 weeks of subcutaneous (s/c) Tocilizumab compared to placebo on health-related quality of life Secondary outcomes - to investigate the effect of 12 weeks of s/c Tocilizumab compared to placebo on: 1) Symptoms 2) Mental Health 3) Physical Performance 4) Daily physical activity 5) Cognitive impairment 6) Multi-Organ function 7) Systemic inflammation To investigate the sustainability of any effect at 12 weeks after medication/placebo cessation on the primary and secondary outcome measures.

Principal Investigator

Dr Emily Fraser

Contact us

Email: samantha.chilcott@ndm.ox.ac.uk

IRAS number

1006298